G1 Therapeutics, Inc. (NASDAQ:GTHX) reported Q4 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $9.84 million.
G1 Therapeutics, Inc. (NASDAQ:GTHX) reported Q4 EPS of ($0.73), $0.08 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $10.25 million versus the consensus estimate of $9.84 million.